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Polymerase chain reaction (PCR) was compared with xenodiagnosis performed 20 years after try-
panocidal chemotherapy to investigate parasite clearance. Eighty-five seropositive individuals for Chagas
disease presenting a positive xenodiagnosis were treated with specific drugs; 37 in the acute phase and
48 in the chronic phase. Fifteen chronic assymptomatic patients received a placebo. Treatment in the
acute phase led to PCR negative results in 73% of the cases, while xenodiagnosis was negative in 86%.
In the chronic phase, PCR was negative in 65% of the patients and 83% led to xenodiagnosis negative
results. Regarding the untreated group (placebo), 73% gave negative results by xenodiagnosis, of which
36% were positive by PCR. Individuals that were considered seronegative (n=10), presented unequivo-
cally negative results in the PCR demonstrating the elimination of parasite DNA. Seventeen individuals
had their antibodies titers decreased to such a level that the final results were considered as doubtful
and 16 of them presented negative PCR. The molecular method represents a clear advantage over
conventional techniques to demonstrate persistent infections in Chagas disease patients that underwent
chemotherapy.
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The persistence of Trypanosoma cruzi in
chronic lesions, revealed by molecular methods,
supports the pathogenesis of Chagas disease me-
diated by presence of the parasite (Jones et al. 1993,
Tarleton et al. 1997, Olivares-Villagómez et al.
1998, Añez et al. 1999). In fact, until recently, the
current view was that auto-immune phenomenon
was the major cause of clinical manifestations of
the disease (Cunha-Neto et al. 1995, 1996). Prob-
ably the auto-immune component is a parasite-in-
duced disorder (Tarleton & Zhang 1999).  There-
fore, etiologic treatment should focus on clearance
of parasites. Most human infections with T. cruzi
are only detected in the chronic phase for which
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treatment is still controversial. Since conventional
serological tests remain positive for years after
successful therapy, a simple and safe procedure to
assess cure is needed (Andrade et al. 1988,
Gazzinelli et al. 1988). Negative xenodiagnosis
and/or haemocultures have been used as evidence
of effective treatment; however, these methods are
time-consuming, laborious, uncomfortable for pa-
tients, and lack sensitivity (Brener et al. 2000). A
complement mediated lysis (CoML) test has been
proposed to monitor treatment (Galvão et al. 1993),
but the requirement for living trypomastigotes lim-
its its use.
Preliminary results revealed the potential use
of polymerase chain reaction (PCR) assay to moni-
tor cure in patients undergoing specific treatment
(Britto et al. 1995). Therefore, we investigated the
use of PCR by comparing the results with xenodi-
agnosis, for evaluating cure in a group of 85 ini-
tially xenopositive patients from two Brazilian
endemic areas who received trypanocidal treatment
in an average of 20 years ago.
A randomized trial of trypanocidal drug ver-
sus placebo treatment in Chagas disease patients
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was carried out in two Brazilian endemic areas in
the 70s, at the Department of Tropical Medicine,
University of Brasília, Federal District of Brazil
(Silveira 2000). In that study 236 patients were
enrolled, 111 in the acute phase and 125 in the
chronic phase, presenting at least two out of three
positive serologic tests for T. cruzi infection and
positive results by xenodiagnosis. Their clinical
state was determined through physical exam, con-
ventional electrocardiography and thoracic radi-
ography. All the individuals examined were diag-
nosed as unquestionably chagasic.  The treated
chronic patients, both who received trypanocidal
drug or placebo were assymptomatic. These same
areas were revisited 20 years afterwards and 99
patients could not be recruited. Eighteen had died,
50 had moved from the districts and no informa-
tion could be gathered from 31 individuals.  From
the 137 remaining patients (40 treated in the acute
phase, 58 treated in the chronic phase and 39 that
received placebo), a subset of 100 individuals (37
treated in the acute phase, 48 treated in the chronic
phase and 15 that received placebo) was selected
for the present study. They were all inhabitants of
two distinct geographic areas: 49 from São Felipe
(State of Bahia) and 51 from Mambai (State of
Goiás), where vector transmission has been inter-
rupted for more than 15 years. Patients were treated
with nifurtimox (7-8 mg/kg/day, 60-90 days) or
benznidazole (5-6 mg/kg/day, 30-60 days) (Silveira
2000).
The patients were followed-up by xenodiag-
nosis in an average of 20 years after treatment
(range = 7-35 years), as previously described
(Marsden et al. 1979). Serology was performed by
indirect immunofluorescence (IIF), indirect hemag-
glutination (IHA) tests and enzyme-linked
immunosorbent assay (ELISA). Patients were con-
sidered positive when their sera reacted in two of
these tests at a dilution of at least 1:80, 1:32 and
1.2 times higher than the cut off, respectively.
Doubtful results corresponded to titers of 1:20 to
1:40 in the IIF, 1:8 to 1:16 in the IHA and results
of 0.9 to 1.1 times higher than the cut off in the
ELISA. PCR amplification of the variable region
of the minicircle molecule was used to detect the
presence of parasite mitochondrial DNA (kineto-
plast DNA) in whole blood, as described elsewhere
(Britto et al. 1993, Wincker et al. 1994). All the
reactions were performed in duplicates and samples
considered to be negative in the PCR assay with T.
cruzi specific primers, were further tested with
human β-globin gene primers, to discard eventual
inhibitors to the PCR test (Wincker et al. 1994).
Furthermore, to enhance the sensitivity of detec-
tion of the amplified products, hybridization ex-
periments were performed in all negative samples
and controls, using kinetoplast DNA from the Y
strain MHOM/BR/00/Y (T. cruzi-II) as a radiola-
beled molecular probe. No samples turned out to
be positive after the hybridization step. Statistical
analysis were performed with a statistical program
of the EPI-INFO package version 6.0 using the Chi-
square and Fisher’s exact tests.
A total of 100 blood samples were analyzed:
85 from patients post-treatment for acute (n=37),
or chronic indeterminate (n=48) Chagas disease,
and 15 from the chronic chagasic assymptomatic
patients that received placebo. Table shows the
results obtained with xenodiagnosis and the PCR
test performed simultaneously with both groups of
treated patients and the placebo group. Treatment
in the acute phase resulted in conversion of xeno-
diagnosis to negative in 32/37 (86%) cases. The
PCR was positive in 5/32 xeno-negative individu-
als plus all of the xeno-positive patients. Of the
treated patients in the indeterminate chronic phase,
40/48 (83%) had become xeno-negative, and PCR
was positive in 9/40 of these and in all the xeno-
positive patients. Overall, PCR was positive in 27%
(10/37 in the acute phase) and 35% (17/48 in the
chronic phase) of treated patients for acute or
chronic phase, respectively.
In the untreated group (placebo), 11 out of 15
individuals were negative by the xenodiagnosis
method (73%), of which 36% were positive by PCR
assay. All 4 xeno-positive patients had positive
PCR results. The low sensitivity of PCR (53%) and
xenodiagnosis (27%) in this group suggests a scarce
parasitaemia. These data reinforce the higher sen-
sitivity of the PCR when compared to xenodiag-
nosis, and suggest its adoption as gold standard
for parasitologic cure.
Of the 27 patients that were treated in the acute
phase and presented negative results by PCR, 5
showed a doubtful serology 20 years afterwards
and 7 had negative serological results. Consider-
ing the patients treated in the chronic phase, nega-
TABLE
Polymerase chain reaction (PCR) results in relation to
xenodiagnosis in samples from treated chagasic
patients and placebo group (untreated chronic
assymptomatic controls). The column Xeno – and
PCR + (bold) represent the advantage of the molecular
technique over the traditional parasitological diagnosis
(N) Xeno + Xeno –
PCR – PCR+ PCR – PCR+
Acute phase 37 0 5 27 5
Chronic phase 48 0 8 31 9
Placebo group 15 0 4 7 4
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tive serological results were evidenced in 3 and 12
showed doubtful results. No patients with an ac-
tual negative serology presented a PCR positive
result (n=10). However, one patient that was treated
in the chronic phase presenting a doubtful sero-
logical result showed T. cruzi DNA amplification.
Indeed, the negative serology was a good marker
for cure in this study since all of them were PCR
negative.
At present, nifurtimox or benznidazole are in-
dicated for the acute T. cruzi infections, for infected
children and also for chronic chagasic patients that
are either in the indeterminate form or in the early
symptomatic stage (Ministério da Saúde 1997).
However, there are many difficulties involved in
the evaluation of the efficacy of parasiticidal treat-
ment mainly during the chronic phase of Chagas
disease (Brener 1984).
PCR presented a higher positivity than the xe-
nodiagnosis method for detecting parasites in all
studied groups, although it was statistically signifi-
cant only in the group comprised of chronic pa-
tients that received trypanocidal drug (17 PCR
positive results versus 8 xenopositive individuals
in 48 patients; χ2=4.34, p=0.03). For instance, 13%
of treated patients in the acute Chagas disease gave
a positive PCR result while the xenodiagnosis had
become negative. In the chronic phase, 18% of the
cases were under-diagnosed by the xenodiagnosis
procedure. These patients that are xeno-negative
and PCR-positive should be followed-up, in order
to demonstrate the role of the presence of circulat-
ing DNA, shown by PCR, in the evolution of symp-
toms. Regarding the untreated group, PCR pre-
sented a negative result in 47% of the cases. This
rate may reflect the intermittent parasitaemia that
is usually found in chronic chagasic patients, even
in those who were treated and did not present para-
sitological cure.
The interpretation of PCR may be raise con-
troversial. A positive result may reflect the detec-
tion of intact parasites or circulating DNA. How-
ever, Tarleton and Zhang (1999) described that
after the intra-muscular injection of large quanti-
ties of kDNA, PCR was positive only for two days
after the injection and not thereafter. The authors
discuss that this study strongly supports the hy-
pothesis that parasite DNA detected by PCR is
derived from intact, extracellular or recently lysed
parasites.
A negative post-treatment PCR result may be
indicative of the absence of parasite DNA at that
moment. In our scenario, as only one point in time
was analyzed, a negative result could not be as-
sumed as definitive cure. In the present study, all
the individuals that became negative by serologi-
cal tests performed 20 years after chemotherapy,
also demonstrated the elimination of circulating
DNA by the PCR method (data not shown). The
agreement of negative results between serology and
PCR, is probably indicative of cure. Although these
data indicate that PCR is more reliable and sensitive
than xenodiagnosis to assess cure after specific treat-
ment, the use of a single assay, as performed in this
setting, is not sufficient to reach a final conclusion
on parasite DNA clearance in post-treatment pa-
tients. Follow-up studies with a continuos screen-
ing of individuals, using the molecular technique
plus serology, should be carried out.
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